ArticleScientific reports2017
Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 63 citations in OpenAlex.
- Redox- and Photo-Responsive FeACS applied materials & interfaces · 2026Article
- CFD Mechanistic Modeling of a Monolithic Chromatography System: Challenges and Opportunities.ACS omega · 2026Review
- Cryogels with controllable physico-chemical properties as advanced delivery systems for biomedical applications.Materials today. Bio · 2025Review
- Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy.Clinical and translational medicine · 2024Review
- Review
- Mesenchymal Stem Cells in Myelodysplastic Syndromes and Leukaemia.Biomedicines · 2024Review
- Effect of lyophilized gelatin-norbornene cryogel size on calvarial bone regeneration.Materials today. Bio · 2023Article
- Cryogels: Advancing Biomaterials for Transformative Biomedical Applications.Pharmaceutics · 2023Review
- Nanocarrier-hydrogel composite delivery systems for precision drug release.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- New horizons of biomaterials in treatment of nerve damage in diabetes mellitus: A translational prospective review.Frontiers in endocrinology · 2022Review
- Engineering hyaluronic acid-based cryogels for CD44-mediated breast tumor reconstruction.Materials today. Bio · 2022Article
- Targeting Brain Tumors with Mesenchymal Stem Cells in the Experimental Model of the Orthotopic Glioblastoma in Rats.Biomedicines · 2021Article
- Glycosaminoglycan-Based Cryogels as Scaffolds for Cell Cultivation and Tissue Regeneration.Molecules (Basel, Switzerland) · 2021Review
- Design and Assessment of Biodegradable Macroporous Cryogels as Advanced Tissue Engineering and Drug Carrying Materials.Gels (Basel, Switzerland) · 2021Review
- Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature.Cancer cell international · 2021Review
- Cryogels: recent applications in 3D-bioprinting, injectable cryogels, drug delivery, and wound healing.Beilstein journal of organic chemistry · 2021Review
- Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy.Oncoimmunology · 2020Article
- Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond.Children (Basel, Switzerland) · 2020Review
- Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy.Frontiers in bioengineering and biotechnology · 2020Review
- T cell immunotherapy enhanced by designer biomaterials.Biomaterials · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combining stem cells with biomaterial scaffolds provides a promising strategy for the development of drug delivery systems. Here we propose an innovative immunotherapeutic organoid by housing human mesenchymal stromal cells (MSCs), gene-modified for the secretion of an anti-CD33-anti-CD3 bispecific antibody (bsAb), in a small biocompatible star-shaped poly(ethylene glycol)-heparin cryogel scaffold as a transplantable and low invasive therapeutic machinery for the treatment of acute myeloid leukemia (AML). The macroporous biohybrid cryogel platform displays effectiveness in supporting proliferation and survival of bsAb-releasing-MSCs overtime in vitro and in vivo, avoiding cell loss and ensuring a constant release of sustained and detectable levels of bsAb capable of triggering T-cell-mediated anti-tumor responses and a rapid regression of CD33
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.